# Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation

> **NCT05761470** · PHASE2 · RECRUITING · sponsor: **Ying Lin** · enrollment: 66 (estimated)

## Conditions studied

- Her-2 Negative Breast Cancer
- HRR Gene Mutation

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Fluzoparib
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT05761470
- **Lead sponsor:** Ying Lin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-06
- **Primary completion:** 2024-06-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2023-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05761470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05761470, "Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05761470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*